HIPEC: Intraperitoneal Chemotherapy
Each year, hundreds of thousands of patients around the world face the diagnosis of "peritoneal carcinomatosis." These include patients with peritoneal mesothelioma, peritoneal pseudomyxoma (PMP) and peritoneal metastasis of primary malignant tumors in another site (colon, ovary for example). Not long ago it was considered virtually intractable and the prognosis of these patients, very poor. Currently, treatment for patients with carcinomatosis is evolving.
Management, which may include HIPEC (high-temperature intraperitoneal chemotherapy) in selected patients, is demanding and complex.
It requires a multidisciplinary effort of specialists with “expertise” in advanced cancer, periotneal metastases as well as cytoreductive surgery plus HIPEC.